Product Details
Product Name:
Larotinib |
CAS No.:
1438072-11-7 |
Purity:
98.45% |
Supply Ability:
10g |
Release date:
2024/11/15 |
Product Introduction
Bioactivity
名稱 | Larotinib |
描述 | Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR. |
體內(nèi)活性 | Larotinib (250, 300, 350 mg; oral; once daily; patients) demonstrated promising antitumor activity and manageable safety profiles in patients with pre-treated advanced ESCC with EGFR overexpression or amplification, especially at the dose of 350 mg, which showed better efficacy and acceptable safety. A phase 3 study is underway on 350 mg larotinib in ESCC patients with EGFR overexpression.[1] |
存儲條件 | Shipping with blue ice. |
溶解度 | DMSO : 60 mg/mL (122.71 mM)
|
相關(guān)產(chǎn)品 | Osimertinib | Lidocaine Hydrochloride hydrate | Lapatinib | Erlotinib hydrochloride | Erlotinib | Neratinib | Chalcone | Genistein | Gefitinib |
相關(guān)庫 | 膜蛋白靶向化合物庫 | 激酶抑制劑庫 | 酪氨酸激酶分子庫 | 抗癌臨床化合物庫 | 藥物功能重定位化合物庫 | 抑制劑庫 | 抗衰老化合物庫 | 已知活性化合物庫 | 抗癌藥物庫 | 抗癌活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:685139-10-0
$88.00 / 1mg
-
CAS:87549-36-8
$58.00 / 1mg
-
CAS:147149-76-6
$35.00 / 1mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$995.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 |